Every spring, millions of people suffering from allergies begin a familiar routine of monitoring pollen counts and seeking relief through medications. However, recent research and therapies are expanding treatment options significantly, moving from a traditional symptom management approach to modifying how the body reacts to allergens. DeVon Preston, an allergist at Cleveland Clinic, notes that this shift allows for a more personalized care strategy. Scott Sicherer, director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, highlights the development of new therapies, including patches and tablets designed to expose the immune system to allergens in innovative ways, with the goal of teaching the immune system to tolerate certain food proteins.
Read More
Allergic reactions stem from the immune system mistakenly identifying harmless substances—such as pollen and pet dander—as threats, resulting in symptoms like sneezing and swelling. Robert Wood, director of the Eudowood Division of Pediatric Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, emphasizes that many patients experience multiple allergic conditions simultaneously, complicating treatment.
Traditionally, allergy treatments have focused on alleviating symptoms with antihistamines and corticosteroids, which do not address the underlying immune dysfunction. In contrast, the goal of newer approaches, such as immunotherapy, is to retrain the immune system to tolerate allergens. This involves administering gradually increasing amounts of an allergen to help the body respond more calmly.
Immunotherapy is not new; allergy shots have been used for decades. However, advancements have made treatment more convenient and accessible. For instance, oral immunotherapy introduces small doses of food allergens to build tolerance. Other methods like sublingual drops and patches are being explored, providing alternatives to injections. Furthermore, new tablets for grass and ragweed allergies allow patients to manage treatment at home.
Personalized medicine is also becoming standard, tailoring treatments based on individual biology and sensitivities. Differentiating between patients’ immune responses can lead to more effective treatments. Research into mRNA-based allergy vaccines is ongoing, although these treatments are still experimental.
Among the most notable breakthroughs are biologics—engineered antibodies that target specific immune pathways. These treatments block cytokines and interleukins, which play a role in allergic responses. Initial trials have shown promise, with 64 percent of participants reporting mild or no symptoms during peak pollen seasons. Despite the smaller scale of many studies, experts view the results as encouraging indicators of potential efficacy.
Biologics are primarily studied and approved for food allergies, but they may also be effective for environmental allergens, as seen in practices in other countries. Wood explains that, while biologics and allergy shots each have their own advantages, they may be most effective when used together.
The notion of “allergy season” varies among individuals. Some may react strongly to seasonal pollen, while others are affected year-round by allergens such as dust and pet dander. Clinicians are learning to adapt care based on geographic factors and environmental conditions.
Despite these advancements, challenges such as treatment affordability and accessibility persist. Matching patients with the right treatment often requires time and tests. Nonetheless, Sicherer emphasizes that there is an exciting shift toward more active and tailored approaches in allergy treatment, noting the significant potential to enhance patients' quality of life and prevent severe allergic reactions. Daryl Austin is a freelance writer based in Salt Lake City, Utah, reporting regularly on health and science for National Geographic.